News•Feb 20, 2026
NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis
U.S. FDA has granted IND clearance for NexEos Bio’s ophthalmic solution NTX-1024, allowing the company to commence a combined Phase II/III clinical trial in vernal keratoconjunctivitis (VKC). The upcoming study will assess safety and efficacy after an open‑label investigator‑initiated trial demonstrated symptom relief and reduced ocular inflammation with good tolerability. NTX-1024 also holds orphan drug designation for VKC, positioning it for potential regulatory incentives. NexEos plans to launch the trial in the second half of 2026.
By PharmaShots
News•Feb 20, 2026
Boehringer Ingelheim and NIPER Sign MoU on Pharmaceutical Research
Boehringer Ingelheim India has signed a memorandum of understanding with the National Institute of Pharmaceutical Education and Research (NIPER) in Raebareli to deepen collaboration on pharmaceutical technologies and novel drug delivery systems. The agreement grants NIPER access to Boehringer’s opnMe...
By Pharmaceutical Technology (GlobalData)
News•Feb 20, 2026
Boehringer Ingelheim Secures US FDA’s EUA for NexGard and NexGard COMBO to Treat NWS
Boehringer Ingelheim received an Emergency Use Authorization (EUA) from the U.S. FDA for its NexGard chewable tablets to treat New World screwworm (NWS) infestations in dogs and puppies, and for NexGard COMBO topical solution to treat NWS in cats and...
By PharmaShots
News•Feb 20, 2026
STAT+: Texas Attorney General Sues Sanofi for Allegedly Providing Kickbacks to Doctors to Prescribe Its Drugs
Texas Attorney General Ken Paxton filed a lawsuit alleging Sanofi paid kickbacks to physicians by offering free nursing staff and insurance‑support services. The alleged scheme was designed to steer prescriptions toward Sanofi’s drugs for chronic conditions such as diabetes, multiple...
By STAT News — Pharma
News•Feb 20, 2026
Amicus Therapeutics Inc (FOLD) Q4 2025 Earnings Call Transcript
Amgen reported double‑digit revenue and earnings growth for 2025, driven by strong performance across its oncology, rare‑disease, biosimilar and general‑medicine portfolios. Fourteen products surpassed $1 billion in sales, with Repatha, Evenity and Tespire each posting over 30% year‑over‑year growth. The company...
By Motley Fool – Earnings Transcripts
News•Feb 19, 2026
Valneva’s Lyme Disease Vaccine Offers Beacon of Hope Amid 2025 Sales Dip
Valneva reported a 3.3% decline in product sales to €157.9 million in 2025, driven primarily by regulatory suspensions of its chikungunya vaccine Ixchiq in the US and UK. Despite the sales dip, total revenue rose to €174.7 million, buoyed by a licensing...
By Pharmaceutical Technology (GlobalData)
News•Feb 19, 2026
DHL Group Invests €2bn in Healthcare Logistics Push
DHL Group announced a €2 billion strategic investment to expand its Life Sciences & Healthcare air‑freight cold‑chain network. The rollout adds more than 30 GDP‑compliant aviation hubs and a dedicated Boeing 777F route between Brussels and Cincinnati, linking Europe’s life‑science cluster...
By Aviation Business News – Cargo
News•Feb 19, 2026
STAT+: Pharmalittle: We’re Reading About the FDA Pushing OTC Meds, Its New Trial Standards, and Much More
The FDA, under Commissioner Marty Makary, is pushing to expand over‑the‑counter (OTC) availability for safe prescription drugs such as nausea treatments and vaginal estrogen. Simultaneously, the agency proposes dropping the long‑standing requirement for two pivotal clinical trials, moving to a...
By STAT News — Pharma
News•Feb 19, 2026
ViiV Healthcare Reports P-III (LATITUDE) Trial of Cabenuva in Adherence-Challenged HIV Patients
ViiV Healthcare presented results from the Phase III LATITUDE trial evaluating Cabenuva, a long‑acting injectable of cabotegravir and rilpivirine, in 453 adults with adherence challenges. Among 306 virally suppressed participants, the quarterly injection reduced cumulative regimen failure to 22.8% versus...
By PharmaShots
News•Feb 19, 2026
Covetrus to Merge with Cencora’s MWI Animal Health in a $3.5B Deal
Covetrus and Cencora have signed a definitive agreement to merge Covetrus with MWI Animal Health, creating a unified animal‑health platform valued at $3.5 billion. Cencora will receive $1.25 billion in cash, $800 million of preferred equity and $1.45 billion of common equity, securing a...
By PharmaShots
News•Feb 19, 2026
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular...
By Pharmaceutical Technology (GlobalData)
News•Feb 19, 2026
Opinion: My Biggest GLP-1 Ethical Problem: Patients Who Don’t Want to Stop
GLP‑1 agonists have moved from scarcity to abundance, reshaping weight‑management practice. In 2023, shortages forced clinicians to ration these drugs, often off‑label for obesity. Today, the surplus creates a new dilemma: patients seeking extreme, unsustainable weight loss and refusing to...
By STAT News — Pharma
News•Feb 18, 2026
STAT+: New FDA Guidance for Antibiotic Use in Food-Producing Animals Prompts Criticism over Antibiotic Resistance
The FDA’s Center for Veterinary Medicine issued new guidance urging drugmakers to add explicit duration limits to medically important antibiotics used in food‑producing animals. Currently, about 28% of these drugs are administered continuously for approved indications, but the guidance seeks...
By STAT News — Pharma
News•Feb 18, 2026
FDA to Review Moderna’s Flu Jab on Agency Pivot
The FDA has reversed its earlier refusal and will now evaluate Moderna’s mRNA‑1010 seasonal flu vaccine using a two‑track approach: a full Biologics License Application review for adults 50‑64 and an accelerated approval pathway for those 65 and older, contingent...
By Pharmaceutical Technology (GlobalData)
News•Feb 18, 2026
Opinion: I Was a Moderna Exec when the Covid Vaccine Rolled Out. That Spirit of Possibility Is No More
Former Moderna executive Richard Hughes IV reflects on the exhilaration of the COVID‑19 vaccine launch, describing a once‑vibrant "spirit of possibility" that drove rapid innovation. He recounts his personal journey from unknown outsider to key player in a global health...
By STAT News — Pharma
News•Feb 17, 2026
STAT+: At Drugmakers’ Forum, Oz Gets a Friendly Embrace, While Makary Faces Tough Questions
At a PhRMA‑hosted forum, CMS Administrator Mehmet Oz engaged warmly with Pfizer CEO Albert Bourla, championing vaccines and proposing closed‑door policy talks and even suggesting industry executives consider government jobs. In contrast, FDA Commissioner Marty Makary was sharply questioned by...
By STAT News — Pharma